Polyplus’ LipidBrick is designed to expand the scope of lipid nanoparticle formulation usage in mRNA therapeutics and vaccine development.
Polyplus, a French provider of solutions for advanced biologic and cell and gene therapy production, announced a novel cationic lipid nanoparticle (LNP) formulation for messenger RNA (mRNA) therapeutic and vaccine development on March 14, 2023. Set for release in April 2023, the LipidBrick IM21.7c is a formulation designed to expand the scope of LNP usage in various therapeutic and oncology applications, as well as prophylactic vaccines.
The formulation is designed to overcome current-generation ionizable lipid challenges used in current LNPs by enabling a wider in-vivo biodistribution and decreasing accumulation in the liver. According to a company press release, proof of concept work demonstrated that it successfully modulates the overall charge of LNPs, improving drug efficiency and formulation stability with no additional safety concerns.
“Polyplus draws on over 20 years legacy in cationic polymer and lipid-based delivery systems for both in-vitro and in-vivo models to power mRNA therapeutics,” said Mario Philips, CEO, Polyplus, in the release. “As we carry forward this legacy, we are working to ensure that our offer opens new possibilities to improve LNP formulation to meet the growing demand of the mRNA therapeutic market. LipidBrick IM21.7c is already used in jetMESSENGER and liposomal formulations for mRNA delivery, as a ready-to-use solution that requires no onsite formulation.”
Source: Polyplus
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Pfizer Obtains Exclusive Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF
July 25th 2025The licensing agreement between the two companies gives Pfizer the rights to develop, manufacture, and commercialize 3SBio’s bispecific antibody, SSGJ-707, which is in clinical trials for the treatment of a variety of cancers.
Mechanistic Hypothesis of Toxicity: Driving Decision Making in Preclinical Translation
July 16th 2025Mechanistic toxicity hypothesis is essential in guiding decision-making and predicting toxicities during the preclinical stages of drug development. The authors highlight the growing importance of integrating advanced technologies like mass spectrometry imaging into toxicology to enhance preclinical translation, foster innovation in therapeutic development, and ultimately improve drug safety and efficacy.